ArticleExperimental hematology & oncology2024

Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting.

Jingyi Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.